Nucleic acid-based therapy approaches for Huntington's disease

Neurology Research International

Volumn 2012, Issue , 2012, Pages

  Vagner, Tatyana ^a   Young, Deborah ^a   Mouravlev, Alexandre ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866156940     PISSN: 20901852     EISSN: 20901860     Source Type: Journal    
DOI: 10.1155/2012/358370     Document Type: Review

References (115)

1. Martin J. B., Gusella J. F., Huntington's disease: pathogenesis and management. The New England Journal of Medicine 1986 315 20 1267 1276 2-s2.0-0022876328 (Pubitemid 17049686)
2. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993 72 6 971 983
3. Reiner A., Albin R. L., Anderson K. D., D'Amato C. J., Penney J. B., Young A. B., Differential loss of striatal projection neurons in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America 1988 85 15 5733 5737 2-s2.0-0001589776
4. Vonsattel J. P. G., DiFiglia M., Huntington disease. Journal of Neuropathology and Experimental Neurology 1998 57 5 369 384 2-s2.0-0031837533 (Pubitemid 28237321)
5. Rigamonti D., Bauer J. H., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M. R., Li Y., Cooper J. K., Ross C. A., Govoni S., Vincenz C., Cattaneo E., Wild-type huntingtin protects from apoptosis upstream of caspase-3. Journal of Neuroscience 2000 20 10 3705 3713 2-s2.0-0034657112 (Pubitemid 30266233)
6. Rigamonti D., Sipione S., Goffredo D., Zuccato C., Fossale E., Cattaneo E., Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. The Journal of Biological Chemistry 2001 276 18 14545 14548 2-s2.0-0035805504 10.1074/jbc.C100044200
7. Leavitt B. R., Van Raamsdonk J. M., Shehadeh J., Fernandes H., Murphy Z., Graham R. K., Wellington C. L., Raymond L. A., Hayden M. R., Wild-type huntingtin protects neurons from excitotoxicity. Journal of Neurochemistry 2006 96 4 1121 1129 2-s2.0-33645100553 10.1111/j.1471-4159.2005.03605.x
8. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J. P., Carraway R., Reeves S. A., Boyce F. M., Aronin N., Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995 14 5 1075 1081 2-s2.0-0028989602
9. Block-Galarza J., Chase K. O., Sapp E., Vaughn K. T., Valle R. B., DiFiglia M., Aronin N., Fast transport and retrograde movement of huntingtin and HAP 1 in axons. NeuroReport 1997 8 9-10 2247 2251 2-s2.0-0030878098 (Pubitemid 27319681)
10. Gauthier L. R., Charrin B. C., Borrell-Pagès M., Dompierre J. P., Rangone H., Cordelières F. P., De Mey J., MacDonald M. E., Lemann V., Humbert S., Saudou F., Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004 118 1 127 138 2-s2.0-3142636768 10.1016/j.cell.2004.06.018 (Pubitemid 38902819)
11. Trushina E., Dyer R. B., Badger J. D., Ure D., Eide L., Tran D. D., Vrieze B. T., Legendre-Guillemin V., McPherson P. S., Mandavilli B. S., Van Houten B., Zeitlin S., McNiven M., Aebersold R., Hayden M., Parisi J. E., Seeberg E., Dragatsis I., Doyle K., Bender A., Chacko C., McMurray C. T., Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Molecular and Cellular Biology 2004 24 18 8195 8209 2-s2.0-4444316194 10.1128/MCB.24.18.8195-8209.2004 (Pubitemid 39167467)
12. Zuccato C., Ciammola A., Rigamonti D., Leavitt B. R., Goffredo D., Conti L., MacDonald M. E., Friedlander R. M., Silani V., Hayden M. R., Timmusk T., Sipione S., Cattaneo E., Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001 293 5529 493 498 2-s2.0-0035919701 10.1126/science.1059581 (Pubitemid 32679077)
13. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., Cataudella T., Leavitt B. R., Hayden M. R., Timmusk T., Rigamonti D., Cattaneo E., Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genetics 2003 35 1 76 83 2-s2.0-0041353535 10.1038/ng1219 (Pubitemid 37048599)
14. Sun Y., Savanenin A., Reddy P. H., Liu Y. F., Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. The Journal of Biological Chemistry 2001 276 27 24713 24718 2-s2.0-0035816627 10.1074/jbc.M103501200
15. Smith R., Brundin P., Li J. Y., Synaptic dysfunction in Huntington's disease: a new perspective. Cellular and Molecular Life Sciences 2005 62 17 1901 1912 2-s2.0-24344461460 10.1007/s00018-005-5084-5 (Pubitemid 41261838)
16. McGeer E. G., McGeer P. L., Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976 263 5577 517 519 2-s2.0-0017090806
17. Beal M. F., Marshall P. E., Burd G. D., Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington's disease. Brain Research 1985 361 1-2 135 145 2-s2.0-0022356170 (Pubitemid 16185394)
18. Beal M. F., Kowall N. W., Ellison D. W., Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986 321 6066 168 171 2-s2.0-0022446150 (Pubitemid 16022019)
19. Roberts R. C., Ahn A., Swartz K. J., Beal M. F., DiFiglia M., Intrastriatal injections of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome. Experimental Neurology 1993 124 2 274 282 2-s2.0-0027730251 10.1006/exnr.1993. 1197 (Pubitemid 24041774)
20. Hantraye P., Riche D., Maziere M., Isacson O., A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Experimental Neurology 1990 108 2 91 104 2-s2.0-0025279038 10.1016/0014-4886(90)90014-J (Pubitemid 20153928)
21. Borlongan C. V., Koutouzis T. K., Freeman T. B., Cahill D. W., Sanberg P. R., Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Research 1995 697 1-2 254 257 2-s2.0-0028862452 10.1016/0006-8993(95)00901-2
22. Guyot M. C., Hantraye P., Dolan R., Palfi S., Maziére M., Brouillet E., Quantifiable bradykinesia, gait abnormalities and Huntington's disease- like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 1997 79 1 45 56 2-s2.0-0030997707 10.1016/S0306-4522(96) 00602-1 (Pubitemid 27244999)
23. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W., Bates G. P., Exon I of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996 87 3 493 506 2-s2.0-16044373842 10.1016/S0092-8674(00)81369-0 (Pubitemid 26374323)
24. Hodgson J. G., Agopyan N., Gutekunst C. A., Leavitt B. R., Lepiane F., Singaraja R., Smith D. J., Bissada N., McCutcheon K., Nasir J., Jamot L., Xiao-Jiang L., Stevens M. E., Rosemond E., Roder J. C., Phillips A. G., Rubin E. M., Hersch S. M., Hayden M. R., A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999 23 1 181 192 2-s2.0-0033136692 10.1016/S0896-6273(00)80764-3 (Pubitemid 29262475)
25. Shelbourne P. F., Killeen N., Hevner R. F., Johnston H. M., Tecott L., Lewandoski M., Ennis M., Ramirez L., Li Z., Iannicola C., Littman D. R., Myers R. M., A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Human Molecular Genetics 1999 8 5 763 774 2-s2.0-0032949459 (Pubitemid 29189043)
26. Lin C. H., Tallaksen-Greene S., Chien W. M., Cearley J. A., Jackson W. S., Crouse A. B., Ren S., Li X. J., Albin R. L., Detloff P. J., Neurological abnormalities in a knock-in mouse model of Huntington's disease. Human Molecular Genetics 2001 10 2 137 144 2-s2.0-0035862896 (Pubitemid 32098123)
27. Menalled L. B., Sison J. D., Wu Y., Olivieri M., Li X. J., Li H., Zeitlin S., Chesselet M. F., Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. Journal of Neuroscience 2002 22 18 8266 8276 2-s2.0-0037107191 (Pubitemid 35379132)
28. Reuter I., Hu M. T. M., Andrews T. C., Brooks D. J., Clough C., Ray Chaudhuri K., Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. Journal of Neurology Neurosurgery and Psychiatry 2000 68 2 238 241 2-s2.0-0034057350 10.1136/jnnp.68.2.238 (Pubitemid 30245854)
29. Blass D. M., Steinberg M., Leroi I., Lyketsos C. G., Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease. American Journal of Psychiatry 2001 158 12 1966 1972 2-s2.0-0035191368 10.1176/appi.ajp.158.12.1966 (Pubitemid 33104100)
30. Ondo W. G., Tintner R., Thomas M., Jankovic J., Tetrabenazine treatment for Huntington's disease-associated chorea. Clinical Neuropharmacology 2002 25 6 300 302 2-s2.0-0036869757 10.1097/00002826-200211000-00003 (Pubitemid 36025267)
31. Kieburtz K., Feigin A., McDermott M., Como P., Abwender D., Zimmerman C., Hickey C., Orme C., Claude K., Sotack J., Greenamyre J. T., Dunn C., Shoulson I., A controlled trial of remacemide hydrochloride in Huntington's disease. Movement Disorders 1996 11 3 273 277 2-s2.0-9244263519 10.1002/mds.870110310 (Pubitemid 26138825)
32. Kremer B., Clark C. M., Almqvist E. W., Raymond L. A., Graf P., Jacova C., Mezei M., Hardy M. A., Snow B., Martin W., Hayden M. R., Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 1999 53 5 1000 1011 2-s2.0-0033595502 (Pubitemid 29442116)
33. Kieburtz K., A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001 57 3 397 404 2-s2.0-0035859843 (Pubitemid 32757583)
34. Marshall F. J., Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003 61 11 1551 1556 2-s2.0-0345600893 (Pubitemid 37505578)
35. Tabrizi S. J., Blamire A. M., Manners D. N., Rajagopalan B., Styles P., Schapira A. H. V., Warner T. T., Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003 61 1 141 142 2-s2.0-0037677341 (Pubitemid 36818771)
36. Thomas M., Ashizawa T., Jankovic J., Minocycline in Huntington's disease: a pilot study. Movement Disorders 2004 19 6 692 695 2-s2.0-4444233214 10.1002/mds.20018 (Pubitemid 39173025)
37. Puri B. K., Leavitt B. R., Hayden M. R., Ross C. A., Rosenblatt A., Greenamyre J. T., Hersch S., Vaddadi K. S., Sword A., Horrobin D. F., Manku M., Murck H., Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005 65 2 286 292 2-s2.0-22544452137 10.1212/01.wnl.0000169025.09670.6d (Pubitemid 41022376)
38. Cho S. R., Benraiss A., Chmielnicki E., Samdani A., Economides A., Goldman S. A., Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. Journal of Clinical Investigation 2007 117 10 2889 2902 2-s2.0-34948855498 10.1172/JCI31778 (Pubitemid 47529619)
39. Frim D. M., Simpson J., Uhler T. A., Short M. P., Bossi S. R., Breakefield X. O., Isacson O., Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. Journal of Neuroscience Research 1993 35 4 452 458 2-s2.0-0027221981 (Pubitemid 23195650)
40. Emerich D. F., Hammang J. P., Baetge E. E., Winn S. R., Implantation of polymer-encapsulated human nerve growth factor-secreting fibroblasts attenuates the behavioral and neuropathological consequences of quinolinic acid injections into rodent striatum. Experimental Neurology 1994 130 1 141 150 2-s2.0-0028574874 10.1006/exnr.1994.1193
41. Martínez-Serrano A., Björklund A., Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. Journal of Neuroscience 1996 16 15 4604 4616 2-s2.0-0029905329 (Pubitemid 26251057)
42. Kordower J. H., Chen E. Y., Winkler C., Fricker R., Charles V., Messing A., Mufson E. J., Wong S. C., Rosenstein J. M., Björklund A., Emerich D. F., Hammang J., Carpenter M. K., Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: trophic and tropic effects in a rodent model of Huntington's disease. Journal of Comparative Neurology 1997 387 1 96 113 2-s2.0-0030885063 10.1002/(SICI)1096-9861(19971013)387:196::AID-CNE8>3.0. CO;2-I (Pubitemid 27419462)
43. Kordower J. H., Charles V., Bayer R., Bartus R. T., Putney S., Walus L. R., Friden P. M., Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proceedings of the National Academy of Sciences of the United States of America 1994 91 19 9077 9080 2-s2.0-0028558577 10.1073/pnas.91.19.9077
44. Venero J. L., Beck K. D., Hefti F., Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA. Neuroscience 1994 61 2 257 268 2-s2.0-0028362474 10.1016/0306-4522(94)90229-1
45. Ramaswamy S., McBride J. L., Herzog C. D., Brandon E., Gasmi M., Bartus R. T., Kordower J. H., Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiology of Disease 2007 26 2 375 384 2-s2.0-34147166160 10.1016/j.nbd.2007.01.003 (Pubitemid 46561340)
46. Ebert A. D., Barber A. E., Heins B. M., Svendsen C. N., Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Experimental Neurology 2010 224 1 155 162 2-s2.0-77953701829 10.1016/j.expneurol.2010.03.005
47. Popovic N., Maingay M., Kirik D., Brundin P., Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Experimental Neurology 2005 193 1 65 74 2-s2.0-16244373680 10.1016/j.expneurol.2004.12.009 (Pubitemid 40463268)
48. Zala D., Bensadoun J. C., De Almeida L. P., Leavitt B. R., Gutekunst C. A., Aebischer P., Hayden M. R., Déglon N., Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Experimental Neurology 2004 185 1 26 35 2-s2.0-0346993604 10.1016/j.expneurol.2003.09.002 (Pubitemid 38010276)
49. Mittoux V., Joseph J. M., Conde F., Palfi S., Dautry C., Poyot T., Bloch J., Deglon N., Ouary S., Nimchinsky E. A., Brouillet E., Hof P. R., Peschanski M., Aebischer P., Hantraye P., Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Human Gene Therapy 2000 11 8 1177 1187 2-s2.0-0034690615 10.1089/10430340050015220 (Pubitemid 30331583)
50. Anderson K. D., Panayotatos N., Corcoran T. L., Lindsay R. M., Wiegand S. J., Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proceedings of the National Academy of Sciences of the United States of America 1996 93 14 7346 7351 2-s2.0-0029900762 10.1073/pnas.93.14.7346 (Pubitemid 26243553)
51. de Almeida L. P., Zala D., Aebischer P., Déglon N., Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiology of Disease 2001 8 3 433 446 2-s2.0-0034979217 10.1006/nbdi.2001.0388 (Pubitemid 32566134)
52. Mittoux V., Ouary S., Monville C., Lisovoski F., Poyot T., Condé F., Escartin C., Robichon R., Brouillet E., Peschanski M., Hantraye P., Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. Journal of Neuroscience 2002 22 11 4478 4486 2-s2.0-0036615771 (Pubitemid 37465664)
53. Bloch J., Bachoud-Lévi A. C., Déglon N., Lefaucheur J. P., Winkel L., Palfi S., Nguyen J. P., Bourdet C., Gaura V., Remy P., Brugières P., Boisse M. F., Baudic S., Cesaro P., Hantraye P., Aebischer P., Peschanski M., Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Human Gene Therapy 2004 15 10 968 975 2-s2.0-5644295321 10.1089/hum.2004.15.968 (Pubitemid 39372573)
54. Lynch G., Kramar E. A., Rex C. S., Jia Y., Chappas D., Gall C. M., Simmons D. A., Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. Journal of Neuroscience 2007 27 16 4424 4434 2-s2.0-34247402598 10.1523/JNEUROSCI.5113-06.2007 (Pubitemid 46640726)
55. Canals J. M., Pineda J. R., Torres-Peraza J. F., Bosch M., Martín-Ibañez R., Muñoz M. T., Mengod G., Ernfors P., Alberch J., Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. Journal of Neuroscience 2004 24 35 7727 7739 2-s2.0-4444350918 10.1523/JNEUROSCI.1197-04.2004 (Pubitemid 39186828)
56. Giralt A., Rodrigo T., Martín E. D., Gonzalez J. R., Milà M., Ceña V., Dierssen M., Canals J. M., Alberch J., Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseC γ activity and glutamate receptor expression. Neuroscience 2009 158 4 1234 1250 2-s2.0-60349130539 10.1016/j.neuroscience.2008.11.024
57. Ferrer I., Goutan E., Marín C., Rey M. J., Ribalta T., Brain-derived neurotrophic factor in Huntington disease. Brain Research 2000 866 1-2 257 261 2-s2.0-0034595722 10.1016/S0006-8993(00)02237-X (Pubitemid 30313028)
58. Cattaneo E., Zuccato C., Tartari M., Normal huntingtin function: an alternative approach to Huntington's disease. Nature Reviews Neuroscience 2005 6 12 919 930 2-s2.0-28644433087 10.1038/nrn1806 (Pubitemid 41753086)
59. Bemelmans A. P., Horellou P., Pradier L., Brunet I., Colin P., Mallet J., Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Human Gene Therapy 1999 10 18 2987 2997 2-s2.0-0033544840 10.1089/10430349950016393
60. Kells A. P., Fong D. M., Dragunow M., During M. J., Young D., Connor B., AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Molecular Therapy 2004 9 5 682 688 2-s2.0-2442702838 10.1016/j.ymthe.2004.02.016 (Pubitemid 38660421)
61. Kells A. P., Henry R. A., Connor B., AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment. Gene Therapy 2008 15 13 966 977 2-s2.0-45749153812 10.1038/gt.2008.23 (Pubitemid 351865753)
62. Frim D. M., Uhler T. A., Short M. P., Ezzedine Z. D., Klagsbrun M., Breakefield X. O., Isacson O., Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. NeuroReport 1993 4 4 367 370 2-s2.0-0027468487 (Pubitemid 23116724)
63. Arancibia S., Silhol M., Moulière F., Meffre J., Höllinger I., Maurice T., Tapia-Arancibia L., Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiology of Disease 2008 31 3 316 326 2-s2.0-49349113732 10.1016/j.nbd.2008.05.012
64. Modlich U., Baum C., Preventing and exploiting the oncogenic potential of integrating gene vectors. The Journal of Clinical Investigation 2009 119 4 755 758 2-s2.0-65249108107 10.1172/JCI38831
65. Mandel R. J., Manfredsson F. P., Foust K. D., Rising A., Reimsnider S., Nash K., Burger C., Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Molecular Therapy 2006 13 3 463 483 2-s2.0-32944470807 10.1016/j.ymthe.2005.11.009 (Pubitemid 43257615)
66. Manfredsson F. P., Mandel R. J., Development of gene therapy for neurological disorders. Discovery Medicine 2010 9 46 204 211 2-s2.0-77953722282
67. Yamamoto A., Lucas J. J., Hen R., Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000 101 1 57 66 2-s2.0-0034737299
68. Hu J., Matsui M., Corey D. R., Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Annals of the New York Academy of Sciences 2009 1175 24 31 2-s2.0-70349469318 10.1111/j.1749-6632.2009.04975.x
69. Wang Y. L., Liu W., Wada E., Murata M., Wada K., Kanazawa I., Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neuroscience Research 2005 53 3 241 249 2-s2.0-26844494370 10.1016/j.neures. 2005.06.021 (Pubitemid 41463777)
70. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., Yoder J., Reeves P., Pandey R. K., Rajeev K. G., Manoharan M., Sah D. W. Y., Zamore P. D., Aronin N., Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proceedings of the National Academy of Sciences of the United States of America 2007 104 43 17204 17209 2-s2.0-36749033738 10.1073/pnas.0708285104 (Pubitemid 350211015)
71. Franich N. R., Fitzsimons H. L., Fong D. M., Klugmann M., During M. J., Young D., AAV vector-mediated RNAi of mutant Huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Molecular Therapy 2008 16 5 947 956 2-s2.0-42549134402 10.1038/mt.2008.50 (Pubitemid 351587106)
72. Harper S. Q., Staber P. D., He X., Eliason S. L., Martins I. H., Mao Q., Yang L., Kotin R. M., Paulson H. L., Davidson B. L., RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proceedings of the National Academy of Sciences of the United States of America 2005 102 16 5820 5825 2-s2.0-20244378556 10.1073/pnas.0501507102 (Pubitemid 40559643)
73. Rodriguez-Lebron E., Denovan-Wright E. M., Nash K., Lewin A. S., Mandel R. J., Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Molecular Therapy 2005 12 4 618 633 2-s2.0-25144464388 10.1016/j.ymthe.2005.05.006 (Pubitemid 41350143)
74. Drouet V., Perrin V., Hassig R., Dufour N., Auregan G., Alves S., Bonvento G., Brouillet E., Luthi-Carter R., Hantraye P., Déglon N., Sustained effects of nonallele-specific huntingtin silencing. Annals of Neurology 2009 65 3 276 285 2-s2.0-65249131740 10.1002/ana.21569
75. Nasir J., Floresco S. B., O'Kusky J. R., Diewert V. M., Richman J. M., Zeisler J., Borowski A., Marth J. D., Phillips A. G., Hayden M. R., Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995 81 5 811 823 2-s2.0-0029055717
76. Auerbach W., Hurlbert M. S., Hilditch-Maguire P., Wadghiri Y. Z., Wheeler V. C., Cohen S. I., Joyner A. L., MacDonald M. E., Turnbull D. H., The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Human Molecular Genetics 2001 10 22 2515 2523 2-s2.0-0035888618 (Pubitemid 33095002)
77. White J. K., Auerbach W., Duyao M. P., Vonsattel J. P., Gusella J. F., Joyner A. L., MacDonald M. E., Huntington is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nature Genetics 1997 17 4 404 410 2-s2.0-0030613177 (Pubitemid 27518388)
78. Wexler N. S., Young A. B., Tanzi R. E., Homozygotes for Huntington's disease. Nature 1987 326 6109 194 197 2-s2.0-0023115076 (Pubitemid 17056590)
79. Myers R. H., Leavitt J., Farrer L. A., Jagadeesh J., McFarlane H., Mastromauro C. A., Mark R. J., Gusella J. F., Homozygote for Huntington disease. The American Journal of Human Genetics 1989 45 4 615 618 2-s2.0-0024432090 (Pubitemid 19261450)
80. Wheeler V. C., Gutekunst C. A., Vrbanac V., Lebel L. A., Schilling G., Hersch S., Friedlander R. M., Gusella J. F., Vonsattel J. P., Borchelt D. R., MacDonald M. E., Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Human Molecular Genetics 2002 11 6 633 640 2-s2.0-0037087771 (Pubitemid 34285134)
81. Wheeler V. C., White J. K., Gutekunst C. A., Vrbanac V., Weaver M., Li X. J., Li S. H., Yi H., Vonsattel J. P., Gusella J. F., Hersch S., Auerbach W., Joyner A. L., MacDonald M. E., Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in Hdh(Q92) and Hdh(Q111) knock-in mice. Human Molecular Genetics 2000 9 4 503 513 2-s2.0-0034163497 (Pubitemid 30154008)
82. Boudreau R. L., McBride J. L., Martins I., Shen S., Xing Y., Carter B. J., Davidson B. L., Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Molecular Therapy 2009 17 6 1053 1063 2-s2.0-67349100160 10.1038/mt.2009.17
83. Boudreau R. L., Martins I., Davidson B. L., Artificial MicroRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and In vivo. Molecular Therapy 2009 17 1 169 175 2-s2.0-58149232358 10.1038/mt.2008.231
84. McBride J. L., Boudreau R. L., Harper S. Q., Staber P. D., Monteys A. M., Martins I., Gilmore B. L., Burstein H., Peluso R. W., Polisky B., Carter B. J., Davidson B. L., Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proceedings of the National Academy of Sciences of the United States of America 2008 105 15 5868 5873 2-s2.0-44449121785 10.1073/pnas.0801775105 (Pubitemid 351758464)
85. Hu J., Liu J., Corey D. R., Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chemistry and Biology 2010 17 11 1183 1188 2-s2.0-78649359013 10.1016/j.chembiol.2010.10.013
86. Pfister E. L., Kennington L., Straubhaar J., Wagh S., Liu W., DiFiglia M., Landwehrmeyer B., Vonsattel J. P., Zamore P. D., Aronin N., Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Current Biology 2009 19 9 774 778 2-s2.0-67349159137 10.1016/j.cub.2009.03.030
87. Zhang Y., Engelman J., Friedlander R. M., Allele-specific silencing of mutant Huntington's disease gene. Journal of Neurochemistry 2009 108 1 82 90 2-s2.0-57249086448 10.1111/j.1471-4159.2008.05734.x
88. Liu W., Kennington L. A., Rosas H. D., Hersch S., Cha J. H., Zamore P. D., Aronin N., Linking SNPs to CAG repeat length in Huntington's disease patients. Nature Methods 2008 5 11 951 953 2-s2.0-56149120246 10.1038/nmeth.1261
89. Schwarz D. S., Ding H., Kennington L., Moore J. T., Schelter J., Burchard J., Linsley P. S., Aronin N., Xu Z., Zamore P. D., Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genetics 2006 2 9 1307 1318 2-s2.0-33749438388 10.137/journal.pgen.0020140 (Pubitemid 44508077)
90. Jacobsen J. C., Gregory G. C., Woda J. M., Thompson M. N., Coser K. R., Murthy V., Kohane I. S., Gusella J. F., Seong I. S., MacDonald M. E., Shioda T., Lee J.-M., jlee51@partners HD CAG-correlated gene expression changes support a simple dominant gain of function. Human Molecular Genetics 2011 20 14 2846 2860 10.1093/hmg/ddr195
91. Perrin V., Régulier E., Abbas-Terki T., Hassig R., Brouillet E., Aebischer P., Luthi-Carter R., Déglon N., Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Molecular Therapy 2007 15 5 903 911 2-s2.0-34247245632 10.1038/mt.sj.6300141 (Pubitemid 46621648)
92. Messer A., Lynch S. M., Butler D. C., Developing intrabodies for the therapeutic suppression of neurodegenerative pathology. Expert Opinion on Biological Therapy 2009 9 9 1189 1197 2-s2.0-68949159773 10.1517/ 14712590903176387
93. Southwell A. L., Ko J., Patterson P. H., Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. Journal of Neuroscience 2009 29 43 13589 13602 2-s2.0-70350543879 10.1523/JNEUROSCI.4286-09.2009
94. Skogen M., Roth J., Yerkes S., Parekh-Olmedo H., Kmiec E., Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease. BMC Neuroscience 2006 7, article 65 2-s2.0-34547237479 10.1186/1471-2202-7-65 (Pubitemid 44822885)
95. Grafton S. T., Mazziotta J. C., Pahl J. J., George -. P. S., Haines J. L., Gusella J., Hoffman J. M., Baxter L. R., Phelps M. E., Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Archives of Neurology 1992 49 11 1161 1167 2-s2.0-0026475301
96. Antonini A., Leenders K. L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., Sanchez-Pernaute R., De Yébenez J. G., Boesiger P., Weindl A., Maguire R. P., Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996 119 part 6 2085 2095 2-s2.0-12644252940 10.1093/brain/119.6.2085 (Pubitemid 27032638)
97. Kuwert T., Lange H. W., Boecker H., Titz H., Herzog H., Aulich A., Wang B. C., Nayak U., Feinendegen L. E., Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. Journal of Neurology 1993 241 1 31 36 2-s2.0-0027441163 10.1007/BF00870669 (Pubitemid 23342424)
98. Browne S. E., Beal M. F., The energetics of Huntington's disease. Neurochemical Research 2004 29 3 531 546 2-s2.0-1542348209 10.1023/B:NERE. 0000014824.04728.dd (Pubitemid 38295004)
99. Beal M. F., Brouillet E., Jenkins B. G., Ferrante R. J., Kowall N. W., Miller J. M., Storey E., Srivastava R., Rosen B. R., Hyman B. T., Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. Journal of Neuroscience 1993 13 10 4181 4192 2-s2.0-0027433553 (Pubitemid 23299942)
100. Browne S. E., Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Annals of the New York Academy of Sciences 2008 1147 358 382 2-s2.0-57649187103 10.1196/annals.1427.018
101. Imarisio S., Carmichael J., Korolchuk V., Chen C. W., Saiki S., Rose C., Krishna G., Davies J. E., Ttofi E., Underwood B. R., Rubinsztein D. C., Huntington's disease: from pathology and genetics to potential therapies. Biochemical Journal 2008 412 2 191 209 2-s2.0-44449131447 10.1042/BJ20071619 (Pubitemid 351758226)
102. Benchoua A., Trioulier Y., Zala D., Gaillard M. C., Lefort N., Dufour N., Saudou F., Elalouf J. M., Hirsch E., Hantraye P., Déglon N., Brouillet E., Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Molecular Biology of the Cell 2006 17 4 1652 1663 2-s2.0-33745392939 10.1091/mbc.E05-07-0607 (Pubitemid 44011583)
103. Puigserver P., Spiegelman B. M., brucespiegelman@dfci.harvard.edu Peroxisome proliferator-activated receptor- γ coactivator 1 α (PGC-1 α): transcriptional coactivator and metabolic regulator. Endocrine Reviews 2003 24 1 78 90 10.1210/er.2002-0012 (Pubitemid 36223280)
104. Ferrante R. J., Kowall N. W., Beal M. F., Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985 230 4725 561 563 2-s2.0-0022343684 (Pubitemid 16169813)
105. Cui L., Jeong H., Borovecki F., Parkhurst C. N., Tanese N., Krainc D., Transcriptional repression of PGC-1 α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006 127 1 59 69 2-s2.0-33749042331 10.1016/j.cell.2006.09.015 (Pubitemid 44466642)
106. St-Pierre J., Drori S., Uldry M., Silvaggi J. M., Rhee J., Jäger S., Handschin C., Zheng K., Lin J., Yang W., Simon D. K., Bachoo R., Spiegelman B. M., Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators. Cell 2006 127 2 397 408 2-s2.0-33749999530 10.1016/j.cell.2006.09.024 (Pubitemid 44572377)
107. Goswami A., Dikshit P., Mishra A., Mulherkar S., Nukina N., Jana N. R., nihar@nbrc.ac.in Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochemical and Biophysical Research Communications 2006 342 1 184 190 10.1016/j.bbrc.2006.01.136 (Pubitemid 43247375)
108. Nucifora F. C., Sasaki M., Peters M. F., Huang H., Cooper J. K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V. L., Dawson T. M., Ross C. A., Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 2001 291 5512 2423 2428 2-s2.0-0035937523 10.1126/science.1056784 (Pubitemid 32231807)
109. Steffan J. S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y. Z., Gohler H., Wanker E. E., Bates G. P., Housman D. E., Thompson L. M., The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proceedings of the National Academy of Sciences of the United States of America 2000 97 12 6763 6768 2-s2.0-12944263711 10.1073/pnas.100110097 (Pubitemid 30412788)
110. Huang C. C., Faber P. W., Persichetti F., Mittal V., Vonsattel J. P., MacDonald M. E., Gusella J. F., Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somatic Cell and Molecular Genetics 1998 24 4 217 233 2-s2.0-0032450856 10.1023/B:SCAM.0000007124.19463.e5 (Pubitemid 29316230)
111. Dunah A. W., Jeong H., Griffin A., Kim Y. M., Standaert D. G., Hersch S. M., Mouradian M. M., Young A. B., Tanese N., Krainc D., Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002 296 5576 2238 2243 2-s2.0-0037150687 10.1126/science.1072613 (Pubitemid 34680312)
112. Bae B. I., Xu H., Igarashi S., Fujimuro M., Agrawal N., Taya Y., Hayward S. D., Moran T. H., Montell C., Ross C. A., Snyder S. H., Sawa A., p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005 47 1 29 41 2-s2.0-21544450545 10.1016/j.neuron.2005.06.005 (Pubitemid 40922848)
113. Rubinsztein D. C., Carmichael J., Huntington's disease: molecular basis of neurodegeneration. Expert Reviews in Molecular Medicine 2003 5 20 1 21 2-s2.0-22344453935
114. Zuccato C., Belyaev N., Conforti P., Ooi L., Tartari M., Papadimou E., MacDonald M., Fossale E., Zeitlin S., Buckley N., Cattaneo E., Widespread disruption of repressor element-1 silencing transcription factor/neuron- restrictive silencer factor occupancy at its target genes in Huntington's disease. Journal of Neuroscience 2007 27 26 6972 6983 2-s2.0-34347364706 10.1523/JNEUROSCI.4278-06.2007 (Pubitemid 47015906)
115. Soldati C., Bithell A., Conforti P., Cattaneo E., Buckley N. J., noel.buckley@kcl.ac.uk Rescue of gene expression by modified REST decoy oligonucleotides in a cellular model of Huntington's disease. Journal of Neurochemistry 2011 116 3 415 425 10.1111/j.1471-4159.2010.07122.x